Alaproclate (GEA-654) is a psychoactive drug and research chemical that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI) and along with zimelidine and indalpine was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies.
This page contains content from the copyrighted Wikipedia article "Alaproclate"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
